Literature DB >> 22911074

Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma.

Jennifer L Gnerlich1, Samuel R Luka, Anjali D Deshpande, Bernard J Dubray, Joshua S Weir, Danielle H Carpenter, Elizabeth M Brunt, Steven M Strasberg, William G Hawkins, David C Linehan.   

Abstract

OBJECTIVE: To correlate microscopic margin status with survival and local control in a large cohort of patients from a high-volume pancreatic cancer center.
DESIGN: Retrospective database review. A uniform procedure for margin analysis was used with 4-color inking (neck, portal vein groove, uncinate, and posterior pancreatic margin) by the surgeon in the operating room.
SETTING: A tertiary care hospital. PATIENTS: We reviewed patients who underwent pancreaticoduodenectomy between September 1, 1997, and December 31, 2008, from a prospective, institutional database. MAIN OUTCOME MEASURES: Using Cox regression models, we identified pathologic characteristics associated with local recurrence (LR) after controlling for potential confounding variables. Overall and LR-free survival curves were generated by the Kaplan-Meier method.
RESULTS: Of 285 patients who underwent pancreaticoduodenectomy for pancreatic adenocarcinoma, 97 (34.0%) had 1 or more positive microscopic margins (uncinate, 16.5%; portal vein groove, 8.8%; neck, 7.7%; and posterior, 10.5%). A total of 198 patients (69.5%) recurred, with the first site of failure being LR only in 47 (23.7%), local plus distant recurrence in 42 (21.2%), and distant recurrence only in 109 (55.1%). Patients with LR only were significantly more likely to have lymph node involvement (adjusted hazard ratio, 2.66; 95% CI, 1.25-5.63) or a positive posterior margin (adjusted hazard ratio, 4.27; 95% CI, 2.07-8.81). Patients with a positive posterior margin had significantly poorer LR-free survival with (P < .001) or without (P = .01) lymph node involvement.
CONCLUSIONS: When systematically assessed, the incidence of positive microscopic margins is high. Positive posterior margins and lymph node involvement were each independently and significantly associated with LR.

Entities:  

Mesh:

Year:  2012        PMID: 22911074     DOI: 10.1001/archsurg.2012.1126

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  52 in total

Review 1.  The role of neoadjuvant therapy in pancreatic cancer: a review.

Authors:  Suzanne Russo; John Ammori; Jennifer Eads; Jennifer Dorth
Journal:  Future Oncol       Date:  2016-02-01       Impact factor: 3.404

2.  Impact of Resection Margin Status in Patients with Pancreatic Cancer: a National Cohort Study.

Authors:  Christof Kaltenmeier; Ibrahim Nassour; Richard S Hoehn; Sidrah Khan; Alison Althans; David A Geller; Alessandro Paniccia; Amer Zureikat; Samer Tohme
Journal:  J Gastrointest Surg       Date:  2020-12-02       Impact factor: 3.452

3.  Resection margins in pancreatic cancer: are we entering a new era?

Authors:  Caroline S Verbeke
Journal:  HPB (Oxford)       Date:  2014-01       Impact factor: 3.647

Review 4.  Resection margins in pancreatic cancer.

Authors:  C S Verbeke
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

5.  Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma.

Authors:  Brian A Boone; Nathan Bahary; Amer H Zureikat; A James Moser; Daniel P Normolle; Wen-Chi Wu; Aatur D Singhi; Phillip Bao; David L Bartlett; Lance A Liotta; Virginia Espina; Patricia Loughran; Michael T Lotze; Herbert J Zeh
Journal:  Ann Surg Oncol       Date:  2015-04-24       Impact factor: 5.344

Review 6.  Beyond the whipple operation: radical resections for cancers of the head of the pancreas.

Authors:  Hans F Schoellhammer; Bryan S Goldner; Joseph Kim; Gagandeep Singh
Journal:  Indian J Surg Oncol       Date:  2013-07-17

7.  A prospective, randomized trial of pancreatectomy combined with isolated hepatic perfusion via a dual route or conventional postoperative adjuvant therapy in patients with advanced pancreatic head carcinoma.

Authors:  Xiaojun He; Yalin Kong; Dongqing Wen; Chengli Liu; Mei Xiao; Gang Zhao; Yuying Zhen; Hongyi Zhang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

8.  En bloc vascular resection for the treatment of borderline resectable pancreatic head carcinoma.

Authors:  Hirohisa Kitagawa; Hidehiro Tajima; Hisatoshi Nakagawara; Isamu Makino; Tomoharu Miyashita; Masatoshi Shoji; Shinichi Nakanuma; Norihiro Hayashi; Hiroyuki Takamura; Tetsuo Ohta; Hiroshi Ohtake
Journal:  Mol Clin Oncol       Date:  2014-02-27

9.  Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation.

Authors:  Steve Walston; Joseph Salloum; Carmine Grieco; Evan Wuthrick; Dayssy A Diaz; Christian Barney; Andrei Manilchuk; Carl Schmidt; Mary Dillhoff; Timothy M Pawlik; Terence M Williams
Journal:  Am J Clin Oncol       Date:  2018-12       Impact factor: 2.339

10.  The addition of radiation to chemotherapy does not improve outcome when compared to chemotherapy in the treatment of resected pancreas cancer: the results of a single-institution experience.

Authors:  Ludmila Katherine Martin; Dai Chu Luu; Xiaobai Li; Peter Muscarella; E Christopher Ellison; Mark Bloomston; Tanios Bekaii-Saab
Journal:  Ann Surg Oncol       Date:  2013-09-18       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.